American Pain Society 2011

Sublingual Dexmedetomidine Shows Analgesic Efficacy in Patients with Chronic Low Back Pain

Patients with chronic low back pain treated with REC1100, a sublingual formulation of dexmedetomidine, showed a significant decrease in mean Visual Analog Scale of Pain (VASPain) scores two hours after dosing compared with those receiving placebo, investigators reported during the American Pain Society’s 30th Annual Scientific Meeting.

Comorbidity, Pain Medication Burden Seen in Patients with Fibromyalgia Newly Prescribed Pregabalin or TCAs

Patients with fibromyalgia (FM) who were prescribed pregabalin and tricyclic antidepressants (TCAs) demonstrated a considerable comorbidity and pain medication burden, investigators reported during the American Pain Society’s 30th Annual Scientific Meeting. In fact, medication use and costs increased in the follow-up period for both cohorts.

Improved Pain, Functioning Observed in Patients with Moderate-to-Severe Osteoarthritis Treated with Fulranumab

Fulranumab, an investigational human recombinant monoclonal antibody (IgG2) to human nerve growth factor (NGF), improved pain and functioning in patients with inadequately controlled moderate-to-severe osteoarthritis pain of the hip and knee, according to results presented reported during the American Pain Society’s 30th Annual Scientific Meeting.

Assessment of Methadone on the QTc-Interval Prolongation

Controversy surrounds the issue of methadone-induced QTc-interval prolongation (QTcP or torsades de pointes), and just who should have EKG testing and when. According to study results presented at the American Pain Society’s 30th Annual Scientific Meeting, there is a dose-dependent effect on QTcP in patients taking <120mg/day of methadone compared with lower doses.